A clinical randomised controlled trial of gamma-transcranial alternating current combined with iTBS to improve cognitive function in patients with Alzheimer's disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500107527

Enrollment

Unknown

Registered

2025-08-13

Start date

2025-08-15

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

gamma-tACS+iTBS group:gamma-tACS+iTBS intervention

gamma-tACS+sham iTBS group:gamma-tACS+sham iTBS intervention

sham gamma-tACS+iTBS group:sham gamma-tACS+iTBS intervention

Eligibility

Sex/Gender

All

Age

65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for AD according to the 10th Revision of the International Statistical Classification of Diseases (ICD-10); 2. MMSE score between 18 and 26 before treatment; 3. CDR score between 1 and 2 before treatment; 4. Age between 65 and 90 years old, with no gender restrictions; 5. Study participants and their guardians voluntarily participate in this study and sign an informed consent form; 6. Patients voluntarily participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Concurrent neurological disorders (including stroke, neuromyelitis optica, Parkinson's disease, epilepsy, etc.); 2. History of epileptic seizures; 3. Presence of metallic objects such as pacemakers, stents, or cochlear implants; 4. Exclusion of vascular, traumatic, or medically induced cognitive decline; 5. Individuals with unstable or severe cardiovascular, pulmonary, hepatic, renal, or haematological disorders (including unstable angina, uncontrolled asthma, active gastrointestinal bleeding, cancer, etc.); 6. Individuals with visual or auditory impairments that prevent them from completing neuropsychological tests and scale assessments.

Design outcomes

Primary

Measure	Time frame
EEG changes;Behavioral tasks;Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog);Adverse Reactions;	—

Secondary

Measure	Time frame
Near infrared functional imaging;nuclear magnetic;Electromyographic changes;	—

Countries

China

Contacts

Public ContactJun Liu

Affiliated Kangning Hospital of Ningbo University

752161872@qq.com+86 574 26302609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026